Changing the paradigm in cardiovascular disease @Novartis
Changing the paradigm in cardiovascular disease  @Novartis
Uploaded January 2023 | Updated November 2026, 7 hours ago
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.

The Company will be a focused on five core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology).

In a recent Meet Novartis Management Investor Relations session, Marie-France Tschudin President, Innovative Medicines International & Chief Commercial Officer at Novartis discusses how cardiovascular disease (CVD) needs to be approached differently for the future.

Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3iPbZTF
Link to Novartis Strategy: bit.ly/3wiCJyW

Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3GW69rn

Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis
Changing the paradigm in cardiovascular diseaseNovartis Campus Lecture - RNA Revolution: A Conversation with Nobel Prize winner Katalin KarikóHealthcare innovation drives well-being and economic growthNovartis transformation into a pure-play Innovative Medicines companyHow does Novartis create value for stakeholders and society?The latest in cancer care: Why Ankur is excitedRedefining CML care at NovartisWhat does belonging mean to you? Lalit’s storyPast Present & Future of CAR-TTaking out cancer’s trashCelebrating International Volunteer Day 2022 - #ThankYouVolunteersRaise Your Voice: Speaking Up About Living With Lung Cancer
Novartis |

Changing the paradigm in cardiovascular disease

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER